Parallel Advisors, LLC - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
Parallel Advisors, LLC ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q3 2023$20,872
+5.2%
2330.0%0.00%0.0%
Q2 2023$19,838
+0.7%
233
-2.1%
0.00%0.0%
Q1 2023$19,695
-28.0%
238
-31.6%
0.00%0.0%
Q4 2022$27,370
+9.5%
348
+2.7%
0.00%0.0%
Q3 2022$25,000
+66.7%
339
+43.6%
0.00%0.0%
Q2 2022$15,000
+7.1%
236
+3.5%
0.00%0.0%
Q1 2022$14,000
+16.7%
228
+3.2%
0.00%
Q4 2021$12,000
-58.6%
221
-46.2%
0.00%
-100.0%
Q3 2021$29,000
+163.6%
411
+160.1%
0.00%
Q2 2021$11,000
-38.9%
158
-3.1%
0.00%
-100.0%
Q1 2021$18,000
-10.0%
163
-1.2%
0.00%0.0%
Q4 2020$20,000
+66.7%
165
+24.1%
0.00%0.0%
Q3 2020$12,000
+9.1%
1330.0%0.00%0.0%
Q2 2020$11,000
-15.4%
1330.0%0.00%0.0%
Q1 2020$13,000
-13.3%
1330.0%0.00%0.0%
Q4 2019$15,000
-21.1%
133
-9.5%
0.00%
-50.0%
Q3 2019$19,000
+18.8%
147
+10.5%
0.00%0.0%
Q2 2019$16,000
+33.3%
1330.0%0.00%
+100.0%
Q1 2019$12,000
-7.7%
1330.0%0.00%
-50.0%
Q4 2018$13,000
-13.3%
1330.0%0.00%0.0%
Q3 2018$15,000
+15.4%
133
-8.3%
0.00%0.0%
Q2 2018$13,000
+18.2%
1450.0%0.00%0.0%
Q1 2018$11,000
+37.5%
1450.0%0.00%
+100.0%
Q4 2017$8,0000.0%1450.0%0.00%0.0%
Q3 2017$8,000
+33.3%
1450.0%0.00%0.0%
Q2 2017$6,000
-40.0%
145
-43.8%
0.00%0.0%
Q1 2017$10,0002580.00%
Other shareholders
HAEMONETICS CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Millrace Asset Group, Inc. 19,264$1,7262.13%
Parkman Healthcare Partners LLC 88,962$7,969,2161.46%
HEARTLAND ADVISORS INC 256,414$24,435,2741.37%
Riverwater Partners LLC 15,553$1,393,2381.27%
KINGDON CAPITAL MANAGEMENT, L.L.C. 111,100$9,952,3381.15%
Lisanti Capital Growth, LLC 78,425$7,025,3121.11%
Aristotle Capital Boston, LLC 311,666$27,919,0540.90%
ROYCE & ASSOCIATES LP 947,550$84,881,5290.86%
CHASE INVESTMENT COUNSEL CORP 18,770$1,6810.84%
Virtus Investment Advisers, Inc. 13,662$1,223,8420.83%
View complete list of HAEMONETICS CORP shareholders